Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $150.65, for a total transaction of $30,130.00. Following the sale, the executive vice president now owns 22,223 shares in the company, valued at approximately $3,347,894.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Michael Patrick Miller also recently made the following trade(s):

  • On Monday, May 15th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $152.98, for a total transaction of $30,596.00.
  • On Monday, April 17th, Michael Patrick Miller sold 200 shares of Jazz Pharmaceuticals PLC stock. The shares were sold at an average price of $152.56, for a total transaction of $30,512.00.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) traded up 1.16% during trading on Tuesday, hitting $152.84. 345,562 shares of the stock traded hands. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75. The stock has a market cap of $9.17 billion, a P/E ratio of 23.09 and a beta of 1.10. The company’s 50 day moving average price is $152.33 and its 200-day moving average price is $135.39.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 EPS for the quarter, missing the Zacks’ consensus estimate of $1.42 by $0.01. The business had revenue of $376.10 million during the quarter, compared to analyst estimates of $376.58 million. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. Jazz Pharmaceuticals PLC’s revenue was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.26 earnings per share. Equities research analysts forecast that Jazz Pharmaceuticals PLC will post $11.00 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

ILLEGAL ACTIVITY WARNING: “Michael Patrick Miller Sells 200 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://transcriptdaily.com/2017/06/20/michael-patrick-miller-sells-200-shares-of-jazz-pharmaceuticals-plc-jazz-stock.html.

JAZZ has been the topic of several analyst reports. Mizuho raised their price target on shares of Jazz Pharmaceuticals PLC from $127.00 to $152.00 and gave the company a “buy” rating in a research report on Tuesday, February 21st. Vetr lowered shares of Jazz Pharmaceuticals PLC from a “strong-buy” rating to a “hold” rating and set a $141.22 price target on the stock. in a research report on Tuesday, February 21st. Evercore ISI initiated coverage on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, February 22nd. They set a “buy” rating and a $160.00 price target on the stock. Stifel Nicolaus dropped their price target on shares of Jazz Pharmaceuticals PLC from $200.00 to $190.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. Finally, Leerink Swann set a $170.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Wednesday, March 1st. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $182.64.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Level Four Advisory Services LLC raised its position in Jazz Pharmaceuticals PLC by 0.8% in the first quarter. Level Four Advisory Services LLC now owns 2,729 shares of the specialty pharmaceutical company’s stock worth $389,000 after buying an additional 23 shares during the period. Mn Services Vermogensbeheer B.V. raised its position in Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares during the period. Stephens Inc. AR raised its position in Jazz Pharmaceuticals PLC by 5.4% in the first quarter. Stephens Inc. AR now owns 1,962 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 100 shares during the period. Eqis Capital Management Inc. raised its position in Jazz Pharmaceuticals PLC by 1.3% in the first quarter. Eqis Capital Management Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock worth $1,625,000 after buying an additional 140 shares during the period. Finally, TD Asset Management Inc. raised its position in Jazz Pharmaceuticals PLC by 0.7% in the first quarter. TD Asset Management Inc. now owns 18,887 shares of the specialty pharmaceutical company’s stock worth $2,741,000 after buying an additional 140 shares during the period. Institutional investors own 88.96% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply